Pittsburgh pharmaceutical company purchases pain medication developer

Pittsburgh-based Consegna Pharma, a drug delivery company, recently purchased Hummelstown-based Fathom Pharma LLC, a company developing long-acting pain medicines.

Fathom is now a wholly owned subsidiary of Consegna Pharma.

Consegna Pharma focuses on areas where long-acting injectable drug delivery systems offer high therapeutic value to reduce deaths from opioid overdoses, treat addiction, and reduce pain. Annually, there are 100,000 drug overdose deaths in the United States.

Fathom Pharma develops treatments for moderate to severe chronic pain that address the safety and efficacy gaps in currently available treatments. Its lead product is being developed to treat chronic pain in terminally ill patients.

“This acquisition is highly complementary to our existing opioid strategy and adds high quality growth potential,” Larry Zana, Consegna Pharma president and CEO, said. “We are delighted to welcome the Fathom team to Consegna.”

By purchasing Fathom Pharma, Consegna Pharma strengthens its ability to develop improved medicines that are potentially less addictive and susceptible to abuse.

“Fathom welcomes joining Consegna, accelerating the clinical development of our combined LAI (long-acting injectables) portfolio focused on several aspects of pain signaling pathways,” Darren Wolfe, Fathom CEO, said. “Across the globe, LAIs are changing the way medicines are delivered in key therapeutic areas, and we are excited to help accelerate this transition.”